Mecamylamine suppresses basal and nicotine- stimulated choroidal neovascularization

Katsuji Kiuchi, Masato Matsuoka, Jenny C. Wu, Raquel Formica, Muralitharan Kengatharan, Mary Verghese, Shinji Ueno, Katsutoshi Yokoi, Naw Htee Khu, John P. Cooke, Peter A Campochiaro

Research output: Contribution to journalArticle

Abstract

Purpose. Nicotinic acetylcholine receptors (nAChR) are best known for their role in neurotransmission, but they have recently been demonstrated on vascular endothelial cells. Ace- tylcholine is their endogenous ligand, but they are also stimulated by nicotine. By stimulating nAChR, nicotine promotes tumor angiogenesis as well as atherosclerotic plaque neovas- cularization. In this study, the authors investigated the role of nAChR in the pathogenesis of choroidal neovascularization (CNV). methods. The effect of the nonselective nAChR antagonist mecamylamine was tested on human retinal and choroidal endothelial cells in vitro and in a murine model of CNV. Results. Several nAChR isoforms were identified in retinal and choroidal microvascular endothelial cells, and the ability of these cells to form tubules when grown in growth factor- reduced basement membrane matrix and supplemented with VEGF was suppressed by the nAChR antagonist mecamylamine. Supplementation of the drinking water of mice with nicotine increased the size of CNV lesions at Bruch membrane rupture sites, an effect that was blocked by subcutaneous administration of mecamylamine (50 mg/ kg/d) by an osmotic pump. In the absence of nicotine, CNV formation was suppressed by the infusion of 50 mg/kg/d mecamylamine or by topical application 0.1 or 1% mecamylamine to the cornea. Conclusions. These data suggest that endogenous activation of nAChR promotes CNV and that activation of nAChR by nicotine may contribute to the increased incidence of CNV seen in smokers with age-related moacular degeneration (AMD). Topically admainistered mecamylamaine could provide an appealing new treatment approach for CNV.

Original languageEnglish (US)
Pages (from-to)1705-1711
Number of pages7
JournalInvestigative Ophthalmology and Visual Science
Volume49
Issue number4
DOIs
StatePublished - Apr 2008

Fingerprint

Mecamylamine
Choroidal Neovascularization
Nicotinic Receptors
Nicotine
Endothelial Cells
Cholinergic Antagonists
Bruch Membrane
Atherosclerotic Plaques
Basement Membrane
Synaptic Transmission
Drinking Water
Cornea
Vascular Endothelial Growth Factor A
Acetylcholine
Rupture
Intercellular Signaling Peptides and Proteins
Protein Isoforms
Ligands
Incidence

ASJC Scopus subject areas

  • Ophthalmology
  • Sensory Systems
  • Cellular and Molecular Neuroscience

Cite this

Mecamylamine suppresses basal and nicotine- stimulated choroidal neovascularization. / Kiuchi, Katsuji; Matsuoka, Masato; Wu, Jenny C.; Formica, Raquel; Kengatharan, Muralitharan; Verghese, Mary; Ueno, Shinji; Yokoi, Katsutoshi; Khu, Naw Htee; Cooke, John P.; Campochiaro, Peter A.

In: Investigative Ophthalmology and Visual Science, Vol. 49, No. 4, 04.2008, p. 1705-1711.

Research output: Contribution to journalArticle

Kiuchi, K, Matsuoka, M, Wu, JC, Formica, R, Kengatharan, M, Verghese, M, Ueno, S, Yokoi, K, Khu, NH, Cooke, JP & Campochiaro, PA 2008, 'Mecamylamine suppresses basal and nicotine- stimulated choroidal neovascularization', Investigative Ophthalmology and Visual Science, vol. 49, no. 4, pp. 1705-1711. https://doi.org/10.1167/iovs.07-0089
Kiuchi, Katsuji ; Matsuoka, Masato ; Wu, Jenny C. ; Formica, Raquel ; Kengatharan, Muralitharan ; Verghese, Mary ; Ueno, Shinji ; Yokoi, Katsutoshi ; Khu, Naw Htee ; Cooke, John P. ; Campochiaro, Peter A. / Mecamylamine suppresses basal and nicotine- stimulated choroidal neovascularization. In: Investigative Ophthalmology and Visual Science. 2008 ; Vol. 49, No. 4. pp. 1705-1711.
@article{3b64190dc8b345eb89b097f98358683d,
title = "Mecamylamine suppresses basal and nicotine- stimulated choroidal neovascularization",
abstract = "Purpose. Nicotinic acetylcholine receptors (nAChR) are best known for their role in neurotransmission, but they have recently been demonstrated on vascular endothelial cells. Ace- tylcholine is their endogenous ligand, but they are also stimulated by nicotine. By stimulating nAChR, nicotine promotes tumor angiogenesis as well as atherosclerotic plaque neovas- cularization. In this study, the authors investigated the role of nAChR in the pathogenesis of choroidal neovascularization (CNV). methods. The effect of the nonselective nAChR antagonist mecamylamine was tested on human retinal and choroidal endothelial cells in vitro and in a murine model of CNV. Results. Several nAChR isoforms were identified in retinal and choroidal microvascular endothelial cells, and the ability of these cells to form tubules when grown in growth factor- reduced basement membrane matrix and supplemented with VEGF was suppressed by the nAChR antagonist mecamylamine. Supplementation of the drinking water of mice with nicotine increased the size of CNV lesions at Bruch membrane rupture sites, an effect that was blocked by subcutaneous administration of mecamylamine (50 mg/ kg/d) by an osmotic pump. In the absence of nicotine, CNV formation was suppressed by the infusion of 50 mg/kg/d mecamylamine or by topical application 0.1 or 1{\%} mecamylamine to the cornea. Conclusions. These data suggest that endogenous activation of nAChR promotes CNV and that activation of nAChR by nicotine may contribute to the increased incidence of CNV seen in smokers with age-related moacular degeneration (AMD). Topically admainistered mecamylamaine could provide an appealing new treatment approach for CNV.",
author = "Katsuji Kiuchi and Masato Matsuoka and Wu, {Jenny C.} and Raquel Formica and Muralitharan Kengatharan and Mary Verghese and Shinji Ueno and Katsutoshi Yokoi and Khu, {Naw Htee} and Cooke, {John P.} and Campochiaro, {Peter A}",
year = "2008",
month = "4",
doi = "10.1167/iovs.07-0089",
language = "English (US)",
volume = "49",
pages = "1705--1711",
journal = "Investigative Ophthalmology and Visual Science",
issn = "0146-0404",
publisher = "Association for Research in Vision and Ophthalmology Inc.",
number = "4",

}

TY - JOUR

T1 - Mecamylamine suppresses basal and nicotine- stimulated choroidal neovascularization

AU - Kiuchi, Katsuji

AU - Matsuoka, Masato

AU - Wu, Jenny C.

AU - Formica, Raquel

AU - Kengatharan, Muralitharan

AU - Verghese, Mary

AU - Ueno, Shinji

AU - Yokoi, Katsutoshi

AU - Khu, Naw Htee

AU - Cooke, John P.

AU - Campochiaro, Peter A

PY - 2008/4

Y1 - 2008/4

N2 - Purpose. Nicotinic acetylcholine receptors (nAChR) are best known for their role in neurotransmission, but they have recently been demonstrated on vascular endothelial cells. Ace- tylcholine is their endogenous ligand, but they are also stimulated by nicotine. By stimulating nAChR, nicotine promotes tumor angiogenesis as well as atherosclerotic plaque neovas- cularization. In this study, the authors investigated the role of nAChR in the pathogenesis of choroidal neovascularization (CNV). methods. The effect of the nonselective nAChR antagonist mecamylamine was tested on human retinal and choroidal endothelial cells in vitro and in a murine model of CNV. Results. Several nAChR isoforms were identified in retinal and choroidal microvascular endothelial cells, and the ability of these cells to form tubules when grown in growth factor- reduced basement membrane matrix and supplemented with VEGF was suppressed by the nAChR antagonist mecamylamine. Supplementation of the drinking water of mice with nicotine increased the size of CNV lesions at Bruch membrane rupture sites, an effect that was blocked by subcutaneous administration of mecamylamine (50 mg/ kg/d) by an osmotic pump. In the absence of nicotine, CNV formation was suppressed by the infusion of 50 mg/kg/d mecamylamine or by topical application 0.1 or 1% mecamylamine to the cornea. Conclusions. These data suggest that endogenous activation of nAChR promotes CNV and that activation of nAChR by nicotine may contribute to the increased incidence of CNV seen in smokers with age-related moacular degeneration (AMD). Topically admainistered mecamylamaine could provide an appealing new treatment approach for CNV.

AB - Purpose. Nicotinic acetylcholine receptors (nAChR) are best known for their role in neurotransmission, but they have recently been demonstrated on vascular endothelial cells. Ace- tylcholine is their endogenous ligand, but they are also stimulated by nicotine. By stimulating nAChR, nicotine promotes tumor angiogenesis as well as atherosclerotic plaque neovas- cularization. In this study, the authors investigated the role of nAChR in the pathogenesis of choroidal neovascularization (CNV). methods. The effect of the nonselective nAChR antagonist mecamylamine was tested on human retinal and choroidal endothelial cells in vitro and in a murine model of CNV. Results. Several nAChR isoforms were identified in retinal and choroidal microvascular endothelial cells, and the ability of these cells to form tubules when grown in growth factor- reduced basement membrane matrix and supplemented with VEGF was suppressed by the nAChR antagonist mecamylamine. Supplementation of the drinking water of mice with nicotine increased the size of CNV lesions at Bruch membrane rupture sites, an effect that was blocked by subcutaneous administration of mecamylamine (50 mg/ kg/d) by an osmotic pump. In the absence of nicotine, CNV formation was suppressed by the infusion of 50 mg/kg/d mecamylamine or by topical application 0.1 or 1% mecamylamine to the cornea. Conclusions. These data suggest that endogenous activation of nAChR promotes CNV and that activation of nAChR by nicotine may contribute to the increased incidence of CNV seen in smokers with age-related moacular degeneration (AMD). Topically admainistered mecamylamaine could provide an appealing new treatment approach for CNV.

UR - http://www.scopus.com/inward/record.url?scp=45549103174&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=45549103174&partnerID=8YFLogxK

U2 - 10.1167/iovs.07-0089

DO - 10.1167/iovs.07-0089

M3 - Article

C2 - 18385094

AN - SCOPUS:45549103174

VL - 49

SP - 1705

EP - 1711

JO - Investigative Ophthalmology and Visual Science

JF - Investigative Ophthalmology and Visual Science

SN - 0146-0404

IS - 4

ER -